IPSEN |
Mercado cerrado -
Otros sitios de cotización
|
Pre-apertura 08:39:31 | |||
| 106,3 EUR | -0,09 % |
|
105,3 | -0,94 % |
Resumen de negocios
- oncología (75,2%);
- neurociencia (21,1%);
- enfermedades raras (3,7%).
A finales de 2023, el grupo contaba con 4 centros de investigación y desarrollo situados en Francia, Reino Unido, Estados Unidos y China, y 4 plantas de fabricación en todo el mundo.
Las ventas netas se distribuyen geográficamente de la siguiente manera: Europa (40,2%), Norteamérica (33,3%) y otros (26,5%).
Número de empleados: 5 325
Ventas por actividad
| EUR en millones | 2022 | Peso | 2023 | Peso | Delta |
|---|---|---|---|---|---|
Oncology
75,2
%
| 2 380 | 78,7 % | 2 351 | 75,2 % | -1,19 % |
Neurosciences
21,1
%
| 604 | 20,0 % | 659 | 21,1 % | +9,08 % |
Rare Diseases
3,7
%
| 41 | 1,4 % | 117 | 3,7 % | +184,43 % |
Ventas por región
| EUR en millones | 2022 | Peso | 2023 | Peso | Delta |
|---|---|---|---|---|---|
Europe
40,2
%
| 1 237 | 40,9 % | 1 257 | 40,2 % | +1,56 % |
North America
33,3
%
| 1 032 | 34,1 % | 1 042 | 33,3 % | +0,94 % |
Rest of the World
26,5
%
| 756 | 25,0 % | 829 | 26,5 % | +9,73 % |
Directores
| Directores | Puesto | Edad | Desde |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 57 | 01/07/20 |
| Director of Finance/CFO | 54 | 03/11/14 | |
| Chairman | 66 | 22/11/10 | |
Sandra Silvestri
CTO | Chief Tech/Sci/R&D Officer | 50 | 05/05/23 |
| Chief Tech/Sci/R&D Officer | 57 | 22/09/23 | |
Aidan Murphy
CTO | Chief Tech/Sci/R&D Officer | 58 | 01/01/18 |
Craig Marks
IRC | Investor Relations Contact | - | - |
| Corporate Officer/Principal | - | 01/03/22 | |
| Corporate Officer/Principal | - | 01/10/20 | |
| Corporate Officer/Principal | 50 | 01/11/21 |
Administradores
| Administradores | Puesto | Edad | Desde |
|---|---|---|---|
Margaret Liu
BRD | Director/Board Member | 66 | 07/06/17 |
Karen Witts
BRD | Director/Board Member | 61 | 21/01/22 |
Michèle Ollier
BRD | Director/Board Member | 65 | 27/05/15 |
| Chairman | 66 | 22/11/10 | |
Henri Beaufour
BRD | Director/Board Member | 59 | 30/08/05 |
Antoine Flochel
BRD | Director/Board Member | 59 | 30/08/05 |
Piet Wigerinck
BRD | Director/Board Member | 58 | 01/05/18 |
David Loew
CEO | Chief Executive Officer | 57 | 01/07/20 |
| Director/Board Member | 44 | 06/11/20 | |
Naomi Binoche
BRD | Director/Board Member | - | - |
Clase de acciones
| Vote | Quantity | Flotante | Autocontrol | Total Float | |
|---|---|---|---|---|---|
| Acción A | 1 | 83 814 526 | 34 798 107 ( 41,52 %) | 1 116 316 ( 1,332 %) | 41,52 % |
Participaciones
Información de la empresa
Empresas del grupo
| Nombre | Categoría y sector |
|---|---|
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. |
Pharmaceuticals: Major
|
Ipsen Pharma Biotech SAS
 Ipsen Pharma Biotech SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma Biotech SAS engages in the pharmaceutical industry. It offers drugs to treat neurology, endocrinology, uro-oncology, hematology, gastroenterology, cardiovascular, and cognitive disorders. The company is headquartered in Signes, France. |
Pharmaceuticals: Major
|
Socapharma SAS
|
Ventas por actividad
Ventas por región
Calificación trading
Calificación Inversor
ESG Refinitiv
B+
Venta
Compra
Recomendación promedio
ACUMULAR
Numero de análisis
15
Último precio de cierre
106,3
EUR
Precio objetivo promedio
124,6
EUR
Diferencia / Objetivo Promedio
+17,24 %
Revisiones del BPA
| Varia. 1 de ene. | Capi. | |
|---|---|---|
| -1,48 % | 9362,68 M | |
| +27,97 % | 672 mil M | |
| +23,58 % | 550 mil M | |
| -7,02 % | 351 mil M | |
| +14,85 % | 317 mil M | |
| +6,25 % | 292 mil M | |
| +2,96 % | 211 mil M | |
| -0,41 % | 203 mil M | |
| -10,02 % | 194 mil M | |
| -11,81 % | 144 mil M |
- Bolsa de valores
- Acciones
- Acción IPN
- Empresa Ipsen
